FDA Cleared Currus Biologics Trial for Solid Tumours
The Phase 1 trial will evaluate a novel CAR T-cell therapy designed to treat advanced refractory cancers.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should medical researchers prioritize developing new therapies for solid tumours?
The U.S. Food and Drug Administration has cleared an Investigational New Drug application for CUR-001, a therapeutic candidate from Melbourne-based Currus Biologics. The company is now cleared to initiate a Phase 1 clinical trial for patients with mesothelin-positive advanced refractory solid tumours.
Why it matters
Solid tumour microenvironments frequently trigger CAR T-cell exhaustion and restrict immune cell infiltration, two major barriers to current cancer treatments. CUR-001 seeks to overcome these obstacles, targeting a disease category that accounts for roughly 90% of all cancer cases.
CUR-001 combines a bispecific antibody platform called BEAT with a FLAG-tagged autologous anti-mesothelin CAR T-cell therapy. The BEAT platform is designed to activate CAR T-cells within lymphoid tissue by engaging both the T-cells and antigen-presenting cells.
The players
Currus Biologics
A Melbourne-based biotechnology company developing specialized cancer therapies that integrate CAR T-cell technology and bispecific antibodies.
U.S. Food and Drug Administration
The federal agency responsible for regulating medical products and clearing human clinical trials in the United States.
The details
The therapy targets mesothelin, a protein frequently expressed on the surface of solid tumour cells. By engineering the CAR T-cells—immune cells modified to recognize specific cancer markers—to interact with the BEAT platform, the treatment aims to maintain cell potency in hostile microenvironments. This approach attempts to bypass the biological barriers that limit the performance of standard CAR T-cell therapies in non-liquid cancers.
Timeline
September 28, 2026: The FDA cleared the Investigational New Drug application.
Early 2027: The first patient in the study is expected to be dosed.
The Tech Race
The development follows a pattern established by the National Cancer Institute's CAR T-cell research program, advancing experimental cellular therapies into human clinical trials. It represents a shift toward addressing solid tumours, which remain a primary hurdle in the race to extend CAR T-cell success beyond blood cancers.
This clinical trial is currently limited to patients with mesothelin-positive advanced refractory solid tumours. Clinical results from this Phase 1 study will be required to establish safety and feasibility before the therapy can move toward broader treatment pathways.
The takeaway
Currus Biologics is moving its proprietary BEAT-enhanced CAR T-cell platform into its first human study. Observers should track the Phase 1 trial results due in early 2027 to see if the therapeutic design successfully maintains T-cell function against solid tumours.
What happens next
The company expects to enroll patients and dose the first participant in the Phase 1 basket study in early 2027.
Further reading
For more on the current state of cancer immunotherapy, see the latest updates in Biotech.
Live Poll
Should medical researchers prioritize developing new therapies for solid tumours?
